Advanced searches left 3/3

Metronomic therapy - Crossref

Summarized by Plex Scholar
Last Updated: 23 June 2022

* If you want to update the article please login/register

Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers

Oral cavity cancers that have arisen locally are treated with a multi-modality approach. Surgery is the most cost-effective local modality in comparison to chemoradiation in oral cancers. Metronomic chemotherapy is being studied as a bridge to surgery and as adjuvant chemotherapy in locally advanced oral cancers. Induction chemotherapy in unresectable oral cancers is unproven. In comparison to intravenous cisplatin, Metronomic chemotherapy has shown improved progression-free survival and overall survival in oral cancers.

Source link: https://doi.org/10.1159/000447579


Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Objects: Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma. As first-line therapy, we initiated a phase II research to determine the safety and effectiveness of adding metronomic chemotherapy to thalidomide. According to Response Evaluation Criteria in Solid Tumors 1. 0, a Tumor examination was carried out. Patients with a Cancer of the Liver Italian Program score of 4, and 31 patients had persistent hepatitis B virus infection. Conclusions: In patients with advanced HCC, the combination of thalidomide and tegafur/uracil was safe and showed limited activity.

Source link: https://doi.org/10.1159/000336126


High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

Objectives: We investigated whether circulating endothelial progenitor and circulating endothelial cell markers were associated with patient survival in patients with acute hepatocellular carcinoma. Methods: Patients with advanced HCC were enrolled in a phase II study comparing a combination of sorafenib and metronomic chemotherapy with tegafur/uracil as a first-line systemic therapy. Conclusion: Patients with advanced HCC receiving sorafenib-based antiangiogenic combination therapy had low baseline CEP values, leading to poor outcomes in patients with severe HCC.

Source link: https://doi.org/10.1159/000331684


Abstract 1125: Altered therapeutic response to metronomic chemotherapy in a metabolic syndrome model of mice bearing a mammary adenocarcinoma: Implication of intestinal ABC transporters

Abstract Breast cancer is one of the most common and fatal cancers worldwide. As key advantages, a novel therapeutic approach is metronomic chemotherapy with continuing, low dose drug administration with therapeutic success and null toxicity as major advantages. We wanted to determine the safety and toxicity of MCT with Cy in mice with metabolic syndrome containing a mammary adenocarcinoma. Throughout the study, CBi male mice were fed on a chow diet and a diet with 40% calories of fat. GII:C+Cy: No cure, GIII: Triple negative mammary adenocarcinoma, mice were dispersed into four groups; when the MFD was clear, mice were able to avoid adenocarcinoma; MIV: HFD+Cy; GII: C no treatment; GIII: HFD+Cy ; GIV: HFD+Cy; HFD relative to C decreased by 64% in efflux of Mrp2 substrate DNP-SG, to C; the transport rate of rhodamine 123 by P-gp decreased 55% in HFD vs. C The tumor volume in GIIvsGI and GIVvsGIII was lower than that of GIV, but it was higher than that of GIV. Microbial ABC transporters in mice bearing a mammary adenocarcinoma may have altered therapeutic response to metronomic chemotherapy, resulting in toxicity. In addition, MCT has lower antitumor activity in animals with MS.

Source link: https://doi.org/10.1158/1538-7445.am2021-1125


Abstract PS11-30: Can metronomic maintenance therapy (MMT) after completion of standard therapy help prevent relapses in patients (Pts) with non-metastatic triple-negative breast cancer (TNBC)

We present a retrospective and prospective review of consecutive Pts treated with TNBC at BKLWalawalkarHospital, Tata Memorial Centre's rural outreach center, wherein the result of TNBC Pts receiving MMT is compared to a historical control group that did not receive the same. Methods: TNBC Pts were either observed or not MMT during standard anthracycline+taxane based therapy, and MMT consisted of two phases: initial 12 weeks of daily oral celecoxib and cyclophosphamide, as well as 12 doses of weekly IV cisplatin. Only Phase I & II MMT was provided to the 93 patients of the 93 remaining Pts initial 25 Pts, but only one patient received Phase I & II MMT, and subsequent 61 Pts received only Phase II MMT. Out of 112 patients 87 received MMT, and nine events were reported, but 25 percent in MMT and 12 events were reported, with 42 percent in non-MMT group 89. 7%. In 7 patients due to Grd2 Mucositis, cyclophosphamide alone was stopped in one patient due to grade 3 exhaustation, MTX and Cyclophosphamide were stopped in 2 patients due to grade 3 fatigue, feverspanic and grade 4 neutropenia, and blood transfusion was performed in them. Patients with non-metastatic triple-negative breast cancer can experience metronomic maintenance therapy after completion of standard therapy [abstract].

Source link: https://doi.org/10.1158/1538-7445.sabcs20-ps11-30


Abstract 2207: Upfront metronomic chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

In recent clinical trials, the survival benefits of combining chemotherapy with concurrent immune checkpoint inhibitors have been demonstrated for squamous cell lung carcinoma — also known as chemoimmunotherapy. However, the real relationship between MTD chemotherapy and ICIs remains tense, as most oncologists believe that MTD chemotherapeutic agents may cause immunosuppression. Methods: In order to make SQCLC cells more dependable to ICIs and improve their chemoimmunotherapy's efficiency, we used the in vitro SQC cell lines, in vivo syngeneic mouse models, and patient samples to fully investigate how to improve the ectopic lymphoid-like cells and the therapeutic goals for anti-programmed death 1 / anti PD-1 ligand monoclonal antibodies, as well as the pharmac SQCLC cells were induced to die by low-dose chemotherapeutic agents by activating the PI3K/Akt/NF-u03baB signaling pathway, thus increasing neoantigen exposure. Following, the high mobility group box-1 released by cells undergoing ICD promoted neoantigen uptake and presentation by inciting dendritic cells and invoking specific T cell responses, prompting specific T cell responses. The effects of regular MTD chemotherapy, however, were additive rather than synergistic, when combined with ICIs. Conclusion: In SQCLC, the upfront metronomic chemotherapy enhances immunotherapy over the standard MTD chemotherapy regimen. [abstract]: In squamous cell lung carcinoma [abstract], Upfront metronomic chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy [abstract]. In:: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. In:: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28; and Jun 22-24.

Source link: https://doi.org/10.1158/1538-7445.am2020-2207


A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.

Abstract #906: Vandetanib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor receptors 2 and 3, as well as the epidermal growth factor receptor. Patients and Methods: Patients and Methods: Patients and Methods: Patients with Stage IV breast cancer were screened for eligibility and tolerability with V and CM in advanced breast cancer; no formal diagnosis was needed; and stable brain metastases were acceptable. In three dose-escalation cohorts: 100 mg qd, 200 mg qd, and 300 mg qd were injected, mts were given CM and V. Pts received V + CM until they became or unacceptable toxicity; dose adjustments were made for treatment-related toxicity. Prioritizing bevacizumab had been helpful in the treatment of visceral disease, 92% had received chemotherapy for metastatic disease, and 38% had received prior bevacizumab. There were two cycles of therapy; the median number of weeks on study was 8 ; median number of weeks was 8. Despite fewer cycles of drug use, elevated toxicity was observed in Cohort 3, which included three episodes of dose-limiting toxicity. One-third of pts required a V dose reduction, but 21% of pts came from a research relating to toxicities, including cerebrovascular disease, pulmonary embolism, rash, abnormal liver function, and myocarditis. In 42% of pts, moderate hypertension was present at a single grade 3 event. paraphrasedoutput:
 Conclusions: The all-oral regimen of V + CM was tolerable at a maximum dose of V 200 mg qd.

Source link: https://doi.org/10.1158/0008-5472.sabcs-906


Abstract A19: Metronomic chemotherapy enhances immunotherapy by preventing stroma-induced immunosuppression

At a high, u201cmaximum tolerated dose, abstract Chemotherapy drugs are typically administered to cancer patients every few weeks at a high, u201cmaximum tolerated dose. Moreover, these recurring tumors are often more aggressive and able to metastasize to other organs, in part because of high doses of C/T drugs in the stromal tissue surrounding tumors, including carcinoma-associated fibroblasts and immune cells. Many human solid tumors are characterized by a prominent stromal reaction characterized by a desmoplastic response produced by CAFs as well as extensive infiltration by immune cell populations, such as tumor-associated macrophages and myeloid-derived suppressor cells. Both the tumor epithelium and the immediate stroma react to systemic C/T, and a therapy-modified stroma can deleteriously influence treatment effectiveness. We have shown that traditional C/T agents such as cyclophosphamide, doxorubicin, gemcitabine, and paclitaxel could paradoxically render CAFs oncogenic in mur models by expanding CSCs, stimulated tumor neovascularization, and promoted immunosuppressive M2 subtype TAM infiltration, leading to tumor recurrence and treatment refractoriness in TAMs, with tumor neo We therefore expect that, although pharmacologic inhibition of CXCR-2 has improved the antitumor safety of immune checkpoint blockade, LDM C/T may be a clinically appropriate alternative to improving immune monitoring in stroma-rich and T-cell inflamed tumors. Given that MTD C/T has positive effects on tumor stemness and immunity, it may be more able to collaborate with emerging CSC-targeted or immunotherapeutics than traditional MTD C/T to help improve the therapeutic results of human solid tumors.

Source link: https://doi.org/10.1158/2326-6074.tumimm18-a19


Abstract B130: Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy

Abstract The efficacy of cancer immunotherapy regimens can be severely hampered by the tumor immune suppressive microenvironment. In Montanide, the vaccine is a multi-peptide combination of universal tumor antigen hTERT epitopes. P. L. E. A. C. Professional compared a standard subcutaneous delivery to a laser-assisted epidermal immunogen delivery by P. L. E. The latter, in fact, creates evenly distributed micropores throughout the epidermis and provides a viable opportunity to rapidly distribute vaccine antigens to Langerhans cells in the epidermis. An interim report shows that the immunogenicity and the therapeutic effect on tumor formation of the vaccine have significantly increased with the introduction of metronomic chemotherapy, as well as the therapeutic effect on tumor formation of the vaccine, and that needle-assisted epidermal immunogen delivery seems to be a highly cost-effective strategy as vaccine delivery. Both immunogenicity and therapeutic effects on tumor growth will be discussed.

Source link: https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b130


Abstract B121: Low dose, metronomic cyclophosphamide therapy sensitizes tumors to CpG-1826 immunotherapy in a preclinical glioma model

Abstract Metronomic chemotherapy, in which cytotoxic drugs are delivered in small doses at regular, intermittent intervals, has shown promising clinical outcomes in several cancers, as well as the benefit of reduced patient exposure compared to traditional maximum tolerated dose chemotherapy. Implanted gliomas by an immune-mediated mechanism, as shown by previous studies. We previously reported that cyclophosphamide therapy on a 6-day repeating metronomic schedule regresses implanted gliomas by an immune-mediated mechanism. Combination of CpG-1826 with metronomic CPA was unable to cause several of these conditions, indicating that TLR9-based immunotherapy can elevate the anti-tumor activity of metronomic CPA by inhibiting feedback immune inhibition mechanisms. Tumors are sensitive to CpG-1826 immunotherapy in a preclinical glioma model in a low dose, metronomic cyclophosphamide therapy. In:: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY; September 16-19, 2015.

Source link: https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b121

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions